Cancer Medications

Arranon is a nucleoside inhibitor approved for refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.

Beleodaq is an HDAC inhibitor approved for relapsed or refractory peripheral T-cell lymphoma.

Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, click here.

Farydak is an HDAC inhibitor approved for multiple myeloma, in combination with dexamethasone and Velcade (bortezomib).

Inqovi is a combination of two oral chemotherapy drugs, decitabine and cedazuridine, used for the treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia.

Xpovio is the first approved nuclear export inhibitor. It is indicated for people with previously treated relapsed or refractory (nonresponsive) multiple myeloma or diffuse large B-cell lymphoma.

Zepzelca is an alkylating drug approved for the treatment of metastatic small-cell lung cancer that has progressed during or after platinum-based chemotherapy.

Zolinza is an HDAC inhibitor approved for people with cutaneous T-cell lymphoma that does not respond to other systemic therapy.

Arimidex is an aromatase inhibitor approved for adjuvant (post-surgery) treatment of hormone receptor-positive (HR+) early breast cancer and first-line or subsequent treatment of HR+ advanced or metastatic breast cancer in postmenopausal women.

Aromasin is an aromatase inhibitor approved for adjuvant (post-surgery) treatment of estrogen receptor-positive (ER+) early breast cancer and treatment of ER+ advanced breast cancer in postmenopausal women who previously used tamoxifen.

Casodex is an androgen receptor inhibitor approved for metastatic prostate cancer.

Erleada is an androgen receptor inhibitor approved for nonmetastatic prostate cancer that progresses despite low testosterone levels (known as castration resistant).

Eulexin is an anti-androgen drug approved for locally confined metastatic prostate cancer.

Evista is a selective estrogen receptor modulator approved for the prevention of breast cancer in high-risk postmenopausal women and women with osteoporosis (bone loss). It is not approved for the treatment of invasive breast cancer or to reduce the risk of cancer recurrence.

Fareston is a selective estrogen receptor modulator approved for the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive tumors or those with unknown receptor status.

Faslodex is an estrogen receptor downregulator approved for the treatment of hormone receptor-positive advanced or metastatic breast cancer in postmenopausal women.

Femara is an aromatase inhibitor approved for adjuvant (post-surgery) treatment of hormone receptor-positive (HR+) early breast cancer and treatment of HR+ advanced breast cancer in postmenopausal women.

Firmagon is a GnRH receptor blocker approved for advanced prostate cancer.

Lupron is a GnRH agonist approved for palliative treatment of advanced prostate cancer. It is also used to treat breast and ovarian cancer, though it is not FDA-approved for these indications.

Nilandron is an anti-androgen drug used to treat men with metastatic prostate cancer after surgical castration, or removal of the testicles.

Nubeqa is an androgen receptor inhibitor approved for the treatment of nonmetastatic prostate cancer that progresses despite low testosterone levels (known as castration-resistant).

Tamoxifen is a selective estrogen receptor modulator approved for adjuvant (post-surgery) treatment to prevent recurrence or spread of early breast cancer and for treatment of women and men with advanced or metastatic breast cancer. It is also used to prevent breast cancer in high-risk women. It is sometimes used to treat ovarian cancer, though it is not FDA-approved for this indication.

Trelstar is a GnRH agonist approved for palliative treatment of advanced prostate cancer.

Vantas is a GnRH agonist approved for palliative treatment of advanced prostate cancer.

Xtandi is an androgen receptor inhibitor approved for metastatic or nonmetastatic prostate cancer that progresses despite low testosterone levels (known as castration-resistant), as well as cancer that remains sensitive to testosterone-blocking therapy.

Zoladex is a GnRH agonist approved for palliative treatment of advanced prostate cancer and, treatment of localized prostate cancer in combination with Eulexin (flutamide) and palliative treatment of breast cancer in premenopausal women. It is also used to treat ovarian cancer, though it is not FDA-approved for this indication.

Zytiga is a CYP17 inhibitor approved for metastatic prostate cancer that progresses despite low testosterone levels (known as castration-resistant) and for high-risk castration-sensitive prostate cancer.

Bavencio is a checkpoint inhibitor approved for advanced or metastatic bladder (urothelial) cancer—both as maintenance therapy and for patients who progress on chemotherapy—metastatic Merkel cell carcinoma and advanced kidney cancer (renal cell carcinoma).

Imfinzi is a checkpoint inhiibtor approved for advanced or metastatic bladder (urothelial) cancer, inoperable non-small-cell lung cancer and extensive-stage small cell lung cancer.

Keytruda is a PD-1 checkpoint inhibitor approved for inoperable or metastatic melanoma, adjuvant treatment of melanoma after surgery, non-small-cell lung cancer, bladder (urothelial) cancer, head and neck cancer, esophageal cancer, liver cancer, kidney cancer, stomach cancer, classic Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, Merkel cell carcinoma, cutaneous squamous cell carcinoma and pre- and post-surgery treatment of triple-negative breast cancer. It is also approved for all metastatic solid tumors with high microsatellite instability or mismatch repair deficiency mutations (MSI-H/dMMR) or high tumor mutation burden. 

Kymriah is a CAR-T therapy approved for relapsed or refractory B-cell acute lymphoblastic leukemia in children and young adults up to age 25 and for relapsed or refractory diffuse large B-cell lymphoma in adults.

Libtayo is a checkpoint inhibitor approved for two types of skin cancer, metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) and advanced basal cell carcinoma, and for advanced or metastatic non-small-cell lung cancer with high PD-L1 expression.

Opdivo is a checkpoint inhibitor approved for inoperable or metastatic melanoma, metastatic or recurrent non-small-cell lung cancer, advanced kidney cancer, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, advanced or metastatic bladder (urothelial) cancer, liver cancer, advanced stomach and esophageal cancer, malignant pleural mesothelioma and colorectal cancer with high microsatellite instability or mismatch repair deficiency genetic mutations. 

Pomalyst is an immunomodulator approved for multiple myeloma and Kaposi sarcoma.

Provenge is a personalized cancer vaccine approved for metastatic prostate cancer that does not respond to hormone therapy (known as castration-resistant).

Revlimid is an immunomodulator approved for multiple myeloma in combination with dexamethasone, for follicular lymphoma and marginal zone lymphomain in combination with Rituxan (rituximab),

and as a single drug for myelodysplastic syndromes and mantle cell lymphoma.

Tecartus is a CAR-T therapy approved for adults with mantle cell lymphoma who have not responded to or who have relapsed after other kinds of treatment.

Tecentriq is a checkpoint inhibitor approved for the treatment of advanced or metastatic bladder (urothelial) cancer, metastatic non-small-cell lung cancer, extensive-stage small-cell lung cancer, metastatic liver cancer and inoperable or metastatic melanoma.

Thalomid is an immunomodulator approved for multiple myeloma, in combination with dexamethasone.

TICE is BCG bacteria approved to treat early-stage bladder (urothelial) cancer and prevent recurrence.

Yervoy is a checkpoint inhibitor approved for advanced or metastatic melanoma, and in combination with Opdivo for kidney cancer (renal cell carcinoma), colorectal cancer with high microsatellite instability or mismatch repair deficiency genetic mutations (MSI-high/dMMR), advanced liver cancer and metastatic or recurrent non-small-cell lung cancer.

Yescarta is a CAR-T therapy approved for relapsed or refractory large B-cell lymphoma in adults, including diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma, and for follicular lymphoma.

Adcetris is a CD30-directed antibody-drug conjugate approved for anaplastic large cell lymphoma and classical Hodgkin lymphoma.

Afinitor is a kinase inhibitor approved for the treatment of hormone receptor-positive, HER2-negative advanced breast cancer in previously treated postmenopausal women, as well as for advanced kidney cancer and advanced or metastatic neuroendocrine tumors of the lung, pancreas, and gastrointestinal tract.

Alecensa is an anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of ALK-positive non-small-cell lung cancer (NSCLC).

Aliqopa is a PI3K kinase inhibitor approved for relapsed follicular lymphoma.

Alunbrig is an anaplastic lymphoma kinase inhibitor approved for the treatment of ALK-positive metastatic non-small-cell lung cancer.

Arzerra is a monoclonal antibody approved for chronic lymphocytic leukemia, and used for the similar blood cancer small lymphocytic lymphoma, alone or in combination with chemotherapy.

Avastin is a VEGF inhibitor approved for the treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer, metastatic kidney cancer (renal cell carcinoma), recurrent or metastatic cervical cancer, recurrent glioblastoma brain cancer, liver cancer, and ovarian, fallopian tube or primary peritoneal cancer. Mvasi and Zirabev are biosimilar medications.

Ayvakit is a kinase inhibitor approved for the treatment of inoperable or metastatic gastrointestinal stromal tumor (GIST) with specific PDGFRA mutations and for advanced systemic mastocytosis.

Balversa is a kinase inhibitor approved for previously treated locally advanced or metastatic bladder cancer (urothelial carcinoma) that carries FGFR genetic mutations.

Besponsa is an antibody-drug conjugate approved for adults with B cell acute lymphoblastic leukemia that does not respond to prior treatment.

Blenrep is a BCMA-directed antibody-drug conjugate approved for people with heavily pretreated relapsed or refractory multiple myeloma.

Blincyto is a bispecific T-cell engager approved for adults and children with B cell acute lymphoblastic leukemia.

Bosulif is a kinase inhibitor approved for adults with newly diagnosed or previously treated Philadelphia chromosome positive (Ph+) chronic myeloid leukemia.

Braftovi is a kinase inhibitor approved as a component of targeted therapy for metastatic melanoma and metastatic colorectal cancer.

Brukinsa is a BTK kinase inhibitor approved the previously treated adults with mantle cell lymphoma.

Cabometyx is a multikinase inhibitor approved for advanced kidney cancer (renal cell carcinoma) and previously treated liver cancer (hepatocellular carcinoma).

Calquence is a BTK kinase inhibitor approved for mantle cell lymphoma and as a first-line or subsequent treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Campath is a targeted therapy approved for people with B-cell chronic lymphocytic leukemia who were previously treated with other medications. It is no longer commercially available for leukemia, but has been rebranded as Lemtrada for multiple sclerosis.

Copiktra is a PI3K kinase inhibitor approved for relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular lymphoma.

Cotellic is a kinase inhibitor approved to treat inoperable or metastatic melanoma with BRAF V600E or V600K mutations in combination with Zelboraf (vemurafenib).

Cyramza is a VEGFR2 inhibitor approved for treatment of cancer of the stomach or gastroesophageal junction (where the stomach meets the esophagus), metastatic non-small-cell lung cancer, metastatic colorectal cancer and inoperable or metastatic liver cancer.

Darzalex is a CD38 inhibitor approved for newly diagnosed or previously multiple myeloma, in combination with various other medications. Darzalex Faspro is a newer formulation that can be given by subcutaneous injection rather than IV infusion.

Daurismo is a hedgehog pathway inhibitor approved for treatment of acute myeloid leukemia in newly diagnosed patients who can't use intensive chemotherapy.

Elzonris is a CD123-directed toxin approved for the treatment of blastic plasmacytoid dendritic cell neoplasm, a rare bone marrow and blood disease that can evolve into leukemia.

Empliciti is a SLAMF7 inhibtor approved multiple myeloma, in combination with dexamethasone and Revlimid (lenalidomide).

Enhertu is a HER2 antibody combined with a chemotherapy drug. It is approved for previously treated people with inoperable or metastatic HER2-positive breast cancer and for people with locally advanced or metastatic HER2-positive stomach or gastroesophageal junction cancer.

Erbitux is an EGFR inhibitor approved for treatment of advanced or metastatic head and neck cancer and EGFR-positive metastatic colorectal cancer without KRAS mutations.

Gazyva is a monoclonal antibody approved for follicular lymphoma and chronic lymphocytic leukemia, and used for the similar blood cancer small lymphocytic lymphoma, in combination with chemotherapy.

Gilotrif is a kinase inhibitor approved for people with metastatic non-small-cell lung cancer (NSCLC) with EGFR mutations who are being treated for the first time or who have experienced disease progression on chemotherapy.

Gleevec, a kinase inhibitor, was one of the first targeted therapies for cancer treatment. It is approved for many indications including Philadelphia chromosome positive (Ph+) chronic myeloid leukemia and acute lymphoblastic leukemia, chronic eosinophilic leukemia, mastocytosis and gastrointestinal stromal tumor.

Herceptin is a HER2 inhibitor approved for adjuvant (post-surgery) therapy of early breast cancer and treatment of metastatic breast cancer, stomach cancer and esophageal cancer that overexpresses human epidermal growth factor receptor 2.

Ibrance is a CDK4/6 kinase inhibitor approved for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in combination with hormone therapy.

Iclusig is a kinase inhibitor approved for adults with chronic myeloid leukemia or acute lymphoblastic leukemia with specific characteristic who are resistant to or cannot use other kinase inhibitors.

Idhifa is an IDH2 inhibitor approved for adults with acute myeloid leukemia with IDH2 mutations that does not respond to prior treatment.

Imbruvica is a BTK kinase inhibitor approved for mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma, marginal zone lymphoma and Waldenstrom macroglobulinemia. It is also used to treat graft-versus-host disease, which can occur after a stem cell transplant.

Inlyta is a kinase inhibitor approved for previously treated advanced kidney cancer (renal cell carcinoma).

Iressa is a tyrosine kinase inhibitor approved for people with metastatic non-small-cell lung cancer (NSCLC) with certain EGFR mutations who are being treated for the first time.

Kadcyla is a HER2 inhibitor combined with a chemotherapy drug. It is approved for people with HER2-positive metastatic breast cancer who were previously treated with Herceptin and chemotherapy and for adjuvant (post-surgery) therapy for early breast cancer.

Kisqali is a CDK4/6 kinase inhibitor approved for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in combination with hormone therapy.

Koselugo is a kinase inhibitor approved for treatment of children with neurofibromatosis type 1 who have inoperable neurofibromas (nerve tumors).

Kyprolis is a proteasome inhibitor approved for relapsed or refractory multiple myeloma, used alone or in combination with other medications.

Lenvima is a multikinase inhibitor approved for treatment of recurrent or metastatic thyroid cancer, previously treated kidney cancer and inoperable liver cancer.

Lorbrena is an anaplastic lymphoma kinase inhibitor approved for the treatment of ALK-positive non-small-cell lung cancer.

Lumoxiti is a CD22-directed toxin approved for adults with hairy cell leukemia that does not respond to prior treatment.

Lynparza is a PARP inhibitor approved for the treatment of advanced ovarian cancer in previously treated people with harmful BRCA mutations, maintenance treatment of ovarian cancer in people responding to chemotherapy, previously treated HER2-negative metastatic breast cancer in people with BRCA mutations, maintenance treatment of pancreatic cancer in people with BRCA mutations and previously treated metastatic castration-resistant prostate cancer in people with BRCA or other faulty DNA repair mutations.

Mekinist is a kinase inhibitor approved to treat certain cancers with BRAF V600 mutations. It can be used alone to treat people with inoperable or metastatic melanoma. It is approved in combination with the companion drug Tafinlar for treatment of inoperable or metastatic melanoma and for prevention of melanoma recurrence after surgery. The combination is also approved for metastatic non-small-cell lung cancer (NSCLC) and advanced thyroid cancer.

Mektovi is a kinase inhibitor approved to treat inoperable or metastatic melanoma with BRAF V600E or V600K mutations in combination with Braftovi (encorafenib).

Monjuvi is a CD19-directed monoclonal antibody approved for the treatment of relapsed or refractory (nonresponsive) diffuse large B-cell lymphoma in combination with Revlimid (lenalidomide).

Mylotarg is a CD33-directed antibody-drug conjugate approved for adults and children with newly diagnosed or relapsed or refractory acute myeloid leukemia.

Nerlynx is a kinase inhibitor approved for extended adjuvant (post-surgery) treatment of early breast cancer that overexpresses human epidermal growth factor receptor 2 in people who previously used Herceptin.

Nexavar is a multikinase inhibitor approved for treatment of inoperable liver cancer that can't be surgically removed, advanced kidney cancer and recurrent or metastatic thyroid cancer.

Ninlaro is a proteasome inhibitor approved multiple myeloma, in combination with dexamethasone and Revlimid (lenalidomide).

Padcev is an antibody-drug conjugate approved for adults with locally advanced or metastatic bladder cancer and other urothelial cancers who previously received PD-1 or PD-L1 checkpoint inhibitors and platinum-based chemotherapy.

Pemazyre is a kinase inhibitor approved for treatment of advanced or metastatic cholangiocarcinoma that carries a specific gene mutation.

Perjeta is a HER2 inhibitor approved for neoadjuvant (pre-surgery) or adjuvant (post-surgery) treatment of early breast cancer, in combination with Herceptin (trastuzumab) and chemotherapy. This combination is also approved for previously untreated metastatic breast cancer.

Phesgo is an injectable fixed-dose combination regimen containing pertuzumab, trastuzumab and hyaluronidase that can be administered by a health care provider at home. It is approved for people with early or metastatic HER2-positive breast cancer.

Piqray is a PI3K kinase inhibitor approved for the treatment of postmenopausal women, and men, with HER2-negative advanced or metastatic breast cancer with PIK3CA mutations.

Polivy is a CD79b-directed antibody-drug conjugate approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in combination with bendamustine and a rituximab product such as Rituxan.

Portrazza is an EGFR inhibitor approved for the first-line treatment of people with metastatic squamous non-small-cell lung cancer (NSCLC) in combination with chemotherapy.

Qinlock is a kinase inhibitor approved for people with previously treated advanced gastrointestinal stromal tumor (GIST).

Retevmo is a kinase inhibitor approved for the treatment of metastatic non-small-cell lung cancer and advanced or metastatic thyroid cancer with RET gene fusions or mutations.

Rituxan is a monoclonal antibody approved for follicular lymphoma, diffuse large B-cell lymphoma and chronic lymphocytic leukemia, and used for the similar blood cancer small lymphocytic lymphoma, alone or in combination with chemotherapy. Truxima and Ruxience are biosimilar medications.

Rozlytrek is approved for the treatment of solid tumors anywhere in the body that have NTRK gene fusions and for ROS1-positive non-small-cell lung cancer.

Rubraca is a PARP inhibitor approved for maintenance treatment of people with recurrent ovarian, fallopian tube or primary peritoneal cancer that is responding to chemotherapy, for previously treated ovarian cancer in patients with harmful BRCA mutations and for previously treated metastatic castration-resistant prostate cancer in people with harmful BRCA mutations.

Rydapt is a kinase inhibitor approved for adults with newly diagnosed acute myeloid leukemia with FLT3 mutations, and for mastocytosis or mast cell leukemia.

Sarclisa is a CD38 inhibitor approved for combination treatment of multiple myeloma in previously treated people.

Sprycel is a kinas inhibitor approved for adults and children with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia or acute lymphoblastic leukemia.

Stivarga is a multikinase inhibitor approved for metastatic colorectal cancer, advanced or metastatic gastrointestinal stromal tumor (GIST) and liver cancer previously treated with Nexavar (sorafenib).

Sutent is a kinase inhibitor approved for treatment of gastrointestinal stromal tumor, pancreatic neuroendocrine tumors and advanced kidney cancer (renal cell carcinoma), and for adjuvant treatment of high-risk kidney cancer after surgery.

Tabrecta is a kinase inhibitor approved for the treatment of metastatic non-small-cell lung cancer with a specific genetic mutation.

Tafinlar is a kinase inhibitor approved to treat certain cancers with BRAF V600 mutations. It can be used alone to treat people with inoperable or metastatic melanoma. It is approved in combination with the companion drug Mekinist for treatment of inoperable or metastatic melanoma and for prevention of melanoma recurrence after surgery. The combination is also approved for metastatic non-small-cell lung cancer (NSCLC) and advanced thyroid cancer.

Tagrisso is a kinase inhibitor approved for people with non-small-cell lung cancer (NSCLC) with certain EGFR mutations.

Talzenna is a PARP inhibitor approved for HER2 negative locally advanced or metastatic breast cancer in people with harmful BRCA mutations.

Tarceva is an EGFR inhibitor approved for the treatment of metastatic non-small-cell lung cancer (NSCLC) with EGFR mutations, and as first-line therapy for locally advanced, inoperable or metastatic pancreatic cancer, in combination with gemcitabine chemotherapy.

Tasigna is a kinase inhibitor approved for newly diagnosed or previously Philadelphia chromosome positive (Ph+) chronic myeloid leukemia.

Tazverik is an EZH2 methyltransferase inhibitor approved for the treatment of inoperable epithelioid sarcoma (a type of soft tissue cancer) and for relapsed or refractory follicular lymphoma.

Tibsovo is an IDH1 inhibitor approved for adults with acute myeloid leukemia with IDH1 mutations that has relapsed or does not respond to prior treatment.

Torisel is a kinase inhibitor approved for the treatment of advanced kidney cancer (renal cell carcinoma).

Trodelvy is an antibody-drug conjugate approved for the treatment of metastatic triple-negative breast cancer and advanced bladder (urothelial) cancer.

Tukysa is a kinase inhibitor approved for use in combination therapy for people with previously treated inoperable or metastatic HER2-positive breast cancer, including cancer that has spread to the brain.

Turalio is a kinase inhibitor approved for the treatment of adults with symptomatic tenosynovial giant cell tumor (TGCT) that is associated with severe functional limitations and cannot be treated with surgery.

Tykerb is a kinase inhibitor approved in combination with chemotherapy for previously treated patients with HER2-positive metastatic breast cancer. It is also approved in combination with hormone therapy for postmenopausal women with both HER2-positive and hormone receptor-positive metastatic cancer.

Vectibix is an EGFR inhibitor approved for treatment of metastatic colorectal cancer without RAS mutations.

Velcade is a proteasome inhibitor approved for multiple myeloma and mantle cell lymphoma.

Venclexta is a BCL-2 inhibitor approved for the treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in previously treated patients, first-line treatment of CLL or SLL in combination with Gazyva (obinutuzumab) and acute myeloid leukemia in patients who can't use intensive chemotherapy.

Verzenio is a CDK4/6 kinase inhibitor approved for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, alone or in combination with hormone therapy.

Vitrakvi is a TRK inhibitor that works against cancers anywhere in the body with NTRK gene fusions.

Vizimpro is a kinase inhibitor approved for people with metastatic non-small-cell lung cancer (NSCLC) with certain EGFR mutations who are being treated for the first time.

Votrient is a multikinase inhibitor approved for the treatment of advanced kidney cancer (renal cell carcinoma) and previously treated soft tissue sarcoma.

Xalkori is a kinase inhibitor approved for the treatment of ALK- or ROS1-positive metastatic non-small-cell lung cancer (NSCLC) and for children and young adults with relapsed or refractory ALK-positive anaplastic large cell lymphoma.

Xospata is a kinase inhibitor approved for treatment of adults with relapsed or refractory acute myeloid leukemia with an FLT3 mutation.

Zaltrap is a VEGF inhibitor approved for treatment of metastatic colorectal cancer that progresses after chemotherapy.

Zejula is a PARP inhibitor approved for the treatment of advanced ovarian, fallopian

tube or primary peritoneal cancer in people with harmful BRCA mutations or genomic instability, as well as for maintenance therapy for people with recurrent or advanced cancer that is responding to platinum chemotherapy.

Zelboraf is a kinase inhibitor approved for inoperable or metastatic melanoma with BRAF V600E mutations and Erdheim-Chester Disease with BRAF V600 mutations.

Zydelig is a PI3K kinase inhibitor approved for relapsed follicular lymphoma, relapsed chronic lymphocytic leukemia and relapsed small lymphocytic lymphoma.

Zykadia is a kinase inhibitor approved for the treatment of ALK-positive metastatic non-small-cell lung cancer (NSCLC).